<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110982">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01950065</url>
  </required_header>
  <id_info>
    <org_study_id>MYO-0806</org_study_id>
    <nct_id>NCT01950065</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety Study of the Iovera Device for the Temporary Reduction in the Appearance of Forehead Wrinkles</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>MyoScience, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MyoScience, Inc</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effectiveness and safety of the iovera device for the temporary reduction in
      the appearance of forehead wrinkles.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement on the 5-point Wrinkle Scale</measure>
    <time_frame>30 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Forehead Wrinkles</condition>
  <arm_group>
    <arm_group_label>Immediate Treatment with iovera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate treatment with iovera</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Treatment with iovera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Delayed Treatment with iovera</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iovera</intervention_name>
    <arm_group_label>Immediate Treatment with iovera</arm_group_label>
    <arm_group_label>Delayed Treatment with iovera</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years

          -  Subject has a forehead wrinkle rating by the Investigator/designee of at least &quot;2&quot; in
             full contraction on the 5-point Wrinkle Scale (5WS) as rated by the study
             Investigator, which, upon physical manipulation/separation of the skin, demonstrates
             a reduction in wrinkle severity

          -  Subject has a glabella wrinkle rating by the Investigator/designee of at least &quot;1&quot; in
             full contraction on the 5-point Glabella Scale (5GS)

          -  Subject has at least a 2 point difference between resting and dynamic forehead
             wrinkle scores using the 5-point Wrinkle Scale (5WS) as rated by the
             Investigator/designee

          -  Subject has Fitzpatrick Skin Type I, II, III, or IV (see Error! Reference source not
             found.)

          -  Subject understands and commits to comply with study requirements

          -  Subject is in good general health and free of any condition that could impair either
             complete study participation or evaluation of forehead wrinkle rating

          -  Subject is willing and able to give written informed consent

        Exclusion Criteria:

          -  Subject has a clotting disorder or coagulopathy that requires regular use of an
             anticoagulant and/or antiplatelet therapy (e.g., warfarin, clopidogrel, etc.)

          -  Subject has used aspirin or any non-steroidal anti-inflammatory drugs (NSAIDs) within
             seven (7) days prior to screening or use of the device

          -  Subject has had prior surgery that alters the subcutaneous anatomy of the target
             treatment sites

          -  Subject has undergone another surgical cosmetic procedure or botulinum toxin
             injection at or above the level of the zygoma (cheekbones) within the past six (6)
             months prior to screening

          -  Subject has a resting wrinkle score of &quot;3&quot; or higher on the 5WS as rated by the study
             Investigator

          -  Subject actively elevates forehead during rest

          -  Subject has been treated with any fillers listed in Error! Reference source not
             found. in the temple or forehead area in the time intervals specified prior to
             screening

          -  Subject has any of the following conditions:

               -  Dermatochalasis with &lt;2mm lid margin when looking straight ahead

               -  Excessive skin laxity/skin aging

               -  Asymmetry in the upper face

               -  History of facial nerve palsy

               -  Eyebrow or eyelid ptosis

               -  History of neuromuscular disorder

               -  Chronic dry eye symptoms

               -  Allergy or intolerance to local anesthetic agents (e.g., Lidocaine)

               -  Use of narcotic medications for a chronic pain condition

               -  Other clinically significant local skin condition (e.g., skin infection) at
                  target treatment site

               -  Any physical or psychiatric condition that in the Investigator's opinion would
                  prevent treatment or adequate study participation

               -  Chronic medical condition that in the Investigator's opinion would affect study
                  participation (such as diabetes, hepatitis, HIV, etc.)

               -  Known diagnosis of cryoglobulinemia, paroxysmal cold hemoglobinuria, or cold
                  urticaria

               -  Subject is known to be noncompliant or is unlikely to comply with the
                  requirements of the study protocol (e.g., due to alcoholism, drug dependency,
                  mental incapacity) in the opinion of the Investigator

          -  Fitzpatrick Skin Type V or VI (see Table 3)

          -  Subject currently enrolled in an investigational drug, biologic or device study that
             could affect the safety or effectiveness of wrinkle treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Roseville Facial Plastic Surgery</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kiener, M.D.</last_name>
      <phone>916-773-0395</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Dayan, M.D.</last_name>
      <phone>855-336-6821</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skin Care Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kaminer, M.D.</last_name>
      <phone>617-731-1600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Geronimus, M.D.</last_name>
      <phone>212-686-7306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nashville Center for Laser and Facial Surgery</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Biesman, M.D.</last_name>
      <phone>615-329-1110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dallas Plastic Surgery Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Jay Burns, M.D.</last_name>
      <phone>214-823-1978</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 20, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
